July 29, 2014 -- Gilead Sciences will allow China and Indian drugmakers to start developing generic formulations of a promising novel HIV/HBV drug, even though the drug’s Phase III tests are still underway. The drug, tenofovir alafenamide (TAF), is a prodrug of the well-known antiretroviral HIV treatment Viread (tenofovir), which is also a Gilead product. China/Indian generic pharmas will be able to market TAF in 112 developing countries – countries that are home to more than 90% of the world’s HIV patients.
Help employers find you! Check out all the jobs and post your resume.
